Orchid Pharma Ltd
NSE:ORCHPHARMA
Gross Margin
Orchid Pharma Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
Orchid Pharma Ltd
NSE:ORCHPHARMA
|
38.4B INR |
41%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
699.5B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
368.8B USD |
69%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
208.7B CHF |
73%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
167.6B GBP |
82%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
186.3B CHF |
75%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
206.3B USD |
81%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
68%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
119.8B EUR |
70%
|
Orchid Pharma Ltd
Glance View
Orchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company is headquartered in Chennai, Tamil Nadu. The firm is involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. The company has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Orchid Pharma Ltd's most recent financial statements, the company has Gross Margin of 41.3%.
You don't have any saved screeners yet